Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Ultra-sensitive detection of clonal m-protein by mass spectrometry enhances detection of residual disease: Results from A phase 1 study of etentamig monotherapy in patients with relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAarif AhsanACAlfred ChungJMJohn McKay

Discussion

Loading...

Member takes

Overview

Phase 1 study shows rapid decline in residual disease markers in patients treated with etentamig, suggesting effective monitoring methods.

Key Points

  • Rapid decline in serum M-protein levels observed in patients treated with etentamig, indicating treatment efficacy.
  • Significant decline noted from median 1.8 g/dL to 0.03 g/dL by C3D1, with P<0.001 highlighting impactful changes.
  • Monoclonal protein detection via mass spectrometry utilized in serum samples during Phase 1 clinical trial for tracking.
  • Supports non-invasive methods for monitoring residual disease in multiple myeloma patients, enhancing patient management.

Cite This Study

Ahsan et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe0https://doi.org/10.1182/blood-2025-5813
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlative biomarker analyses of etentamig in patients with Relapsed/Refractory multiple myeloma (RRMM) at optimal dose support its potential to maximize T-cell activity with rapid and transient proinflammatory cytokine responses2025
  2. 2Clonotypic peptide mass spectrometry to monitor m-protein reduction in patients with relapsed/refractory multiple myeloma from ikema Study2025
  3. 3Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  4. 4Etentamig plus pomalidomide-dexamethasone combination therapy in relapsed or refractory multiple myeloma: A phase 1b dose-escalation and safety expansion study2025 · 2 citations
  5. 5Sensitive peripheral residual disease (PRD) detection using clonotypic mass spectrometry (EasyM) in patients with newly diagnosed multiple myeloma (NDMM)2025